RxDoctor Payments Data

Allison Allen

Nurse Practitioner · Langhorne, PANPI 1184100117

Payments from drug & device makers

$3,209in general payments, 2019–2025

Across 121 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$628
  • Sumitomo Pharma America, Inc.$464
  • AbbVie$391
  • Astellas Pharma US Inc$166
  • Abbott$135
  • Johnson & Johnson$120
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,05995%
  • Education$1505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,209 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$47,012
Medicare patients
274
Services billed
1,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron50$43,169
MyrbetriqMirabegron37$20,215
NatestoTestosterone18$15,242
XyostedTestosterone Enanthate14$9,319
Testosterone46$7,521
Tamsulosin Hcl176$4,096
Methenamine Hippurate24$2,291
Tadalafil43$2,150
ClomidClomiphene Citrate12$1,649
Finasteride74$1,005
Cefdinir78$746
Estradiol13$736
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst75$692
Solifenacin Succinate26$604
Alfuzosin Hcl ErAlfuzosin Hcl39$598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$464$43,16950 claims
Astellas Pharma US IncMyrbetriq$166$20,21537 claims
Antares Pharma, Inc.Xyosted$57$9,31914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →